Works about NILOTINIB

Results: 547

TGFB 2 RS79375991 GENE POLYMORPHISM IN IRAQI CHRONIC MYELOID LEUKEMIA PATIENTS INFECTIOUS WITH HUMAN HERPES VIRUS-8.

Published in:

Obstetrics & Gynaecology Forum, 2024, v. 34, n. 3, p. 1764

By:

Issa, Narjis Ehsan;
Al. Alwany, Shakir H. Mohammed

Publication type:

Article

Pharmacokinetic profile of novel reduced-dose Danziten™ (nilotinib tablets) versus Tasigna® (nilotinib capsules): in vivo bioequivalence and population pharmacokinetic analysis.

Published in:

Cancer Chemotherapy & Pharmacology, 2025, v. 95, n. 1, p. 1, doi. 10.1007/s00280-025-04777-6

By:

Mauro, Michael;
Radich, Jerald;
Jain, Paras;
Sequeira, David;
Bellanti, Francesco;
Douer, Dan

Publication type:

Article

Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience.

Published in:

Indian Journal of Pharmacology, 2022, v. 54, n. 5, p. 349, doi. 10.4103/ijp.ijp_844_21

By:

Swain, Trupti;
Goutam, Siddhartha;
Jena, Rabindra;
Rout, Niranjan

Publication type:

Article

Dried blood spot sampling of nilotinib in patients with chronic myeloid leukaemia: a comparison with venous blood sampling.

Published in:

Journal of Pharmacy & Pharmacology, 2017, v. 69, n. 10, p. 1265, doi. 10.1111/jphp.12757

By:

Boons, Christel C.L.M.;
Chahbouni, Abdel;
Schimmel, Anneliene M.;
Wilhelm, Abraham J.;
Hartog, Yvonne M.;
Janssen, Jeroen J.W.M.;
Hendrikse, N. Harry;
Hugtenburg, Jacqueline G.;
Swart, Eleonora L.

Publication type:

Article

QUANTITATIVE ANALYSIS OF SORAFENIB AND NILOTINIB IN HUMAN PLASMA BY SPE-LC-MS.

Published in:

Farmacia, 2023, v. 71, n. 5, p. 1024, doi. 10.31925/farmacia.2023.5.17

By:

POPESCU, MONICA DENISA ELENA;
MANDA, COSTEL-VALENTIN;
CALUCICĂ, DANIELA MARIA;
GĂMAN, AMELIA MARIA;
NEAMȚU, JOHNY;
BIȚĂ, ANDREI;
MATEESCU, OLIVIA GAROFIȚA;
NEAMȚU, SIMONA-DANIELA;
RĂILEANU, ȘTEFAN;
STANCA, LILIANA;
CROITORU, OCTAVIAN

Publication type:

Article

Chemical Modification of Curcumin into Its Semi-Synthetic Analogs Bearing Pyrimidinone Moiety as Anticancer Agents.

Published in:

Plants (2223-7747), 2022, v. 11, n. 20, p. 2737, doi. 10.3390/plants11202737

By:

Afzal, Obaid;
Yusuf, Mohammad;
Ahsan, Mohamed Jawed;
Altamimi, Abdulmalik S. A.;
Bakht, Md. Afroz;
Ali, Amena;
Salahuddin

Publication type:

Article

DDR1 inhibition as a new therapeutic strategy for colorectal cancer.

Published in:

Molecular & Cellular Oncology, 2018, v. 5, n. 4, p. 1, doi. 10.1080/23723556.2018.1465882

By:

Sirvent, Audrey;
Lafitte, Marie;
Roche, Serge

Publication type:

Article

Identification of novel BCR::ABL1 kinase domain mutation in patients with chronic myeloid leukaemia and imatinib resistance.

Published in:

Malaysian Journal of Pathology, 2024, v. 46, n. 3, p. 431

By:

Yusoff, Yuslina Mat;
Seman, Zahidah Abu;
Anoar, Sharifah Zahra;
Muhamed Said, Siti Shahrum;
Azman, Norazlina;
Kamaluddin, Nor Rizan;
Abdullah, Julia;
Yacob, Aliza Mohd;
Esa, Ezalia

Publication type:

Article

H396P mutation in chronic myeloid leukaemia patient on nilotinib - A case report.

Published in:

Malaysian Journal of Pathology, 2021, v. 43, n. 1, p. 63

By:

JAMALI, Nor Syazana;
RAJA SABUDIN, Raja Zahratul Azma;
ALAUDDIN, Hafiza;
ITHNIN, Azlin;
TUMIAN, Nor Rafeah;
JALIL, Norunaluwar;
AWAI, Rinie;
ABU AMIS, Siti Hawa;
SHUIB, Salwati

Publication type:

Article

Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?

Published in:

Malaysian Journal of Pathology, 2017, v. 39, n. 2, p. 107

By:

Yap, E.;
Tumian, N. R.;
Azma, R. Z.;
Sharifah, N. A.;
Salwati, S.;
Hamidah, N. H.;
Elias, M. H.;
Wong, C. L.

Publication type:

Article

Oral Implant Treatment for a Patient Undergoing Molecularly Targeted Drug Therapy for Chronic Myelocytic Leukemia: A Case Report.

Published in:

2020

By:

Koji Morita;
Hiroki Tsuka;
Koi-chi Kuremoto;
Kazuhiro Tsuga;
Morita, Koji;
Tsuka, Hiroki;
Kuremoto, Koi-Chi;
Tsuga, Kazuhiro

Publication type:

journal article

Quality of life among chronic myeloid leukemia patients in the second-line treatment with nilotinib and influential factors.

Published in:

Quality of Life Research, 2022, v. 31, n. 3, p. 733, doi. 10.1007/s11136-021-02952-9

By:

Nguyen, Cuc Thi Thu;
Nguyen, Binh Thanh;
Nguyen, Thuy Thi Thu;
Petrelli, Fabio;
Scuri, Stefania;
Grappasonni, Iolanda

Publication type:

Article

Comparative analysis of endothelial function measures in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.

Published in:

Acta Haematologica Polonica, 2022, v. 53, n. A, p. 37

By:

Szczepanek, Elżbieta;
Marczyk, Brygida;
Chukwu, Ositadima;
Chłopicki, Stefan;
Sacha, Tomasz

Publication type:

Article

A novel t(3;12)(q21;p13) translocation in a patient with accelerated chronic myeloid leukemia after imatinib and nilotinib therapy.

Published in:

Cancer Biology & Medicine, 2013, v. 10, n. 1, p. 47, doi. 10.7497/j.issn.2095-3941.2013.01.008

By:

Bennour, Ayda;
Tabka, Ikram;
Youssef, Yosra Ben;
Kmeira, Zahra;
Khelif, Abderrahim;
Saad, Ali;
Sennana, Halima

Publication type:

Article

Nilotinib induction of melanogenesis via reactive oxygen species‐dependent JNK activation in B16F0 mouse melanoma cells.

Published in:

Experimental Dermatology, 2018, v. 27, n. 12, p. 1388, doi. 10.1111/exd.13797

By:

Chang, Shao‐Ping;
Huang, Huei‐Mei;
Shen, Shing‐Chuan;
Lee, Woan‐Ruoh;
Chen, Yen‐Chou

Publication type:

Article

A machine learning approach for thermodynamic modeling of the statically measured solubility of nilotinib hydrochloride monohydrate (anti-cancer drug) in supercritical CO2.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-40231-4

By:

Nateghi, Hassan;
Sodeifian, Gholamhossein;
Razmimanesh, Fariba;
Mohebbi Najm Abad, Javad

Publication type:

Article

Concentration of low-density lipoproteins (LDL) is significantly reduced after nilotinib discontinuation.

Published in:

Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-39057-x

By:

Roa-Chamorro, Ricardo;
Puerta-Puerta, José Manuel;
Torres-Quintero, Lucía;
Jaén-Águila, Fernando;
González-Bustos, Pablo;
Rodríguez-Gil, Miguel Ángel;
Mediavilla-García, Juan Diego

Publication type:

Article

Molecular Docking and the Pharmacokinetic Properties of the Anti-Viral Compounds Towards SARS-CoV-An In-silico Approach.

Published in:

International Journal of Pharmaceutical Research & Allied Sciences, 2023, v. 12, n. 1, p. 1, doi. 10.51847/Z2mkWovOqC

By:

Devi, Parthiban Brindha;
Asthana, Yashi;
Sumitha, Arumugam;
Sagayaraj, Ivo Romauld

Publication type:

Article

Treatment discontinuation following low-dose TKIs in 248 chronic myeloid leukemia patients: Updated results from a campus CML real-life study.

Published in:

Frontiers in Pharmacology, 2023, v. 14, p. 1, doi. 10.3389/fphar.2023.1154377

By:

Iurlo, A.;
Cattaneo, D.;
Consonni, D.;
Castagnetti, F.;
Miggiano, M. C.;
Binotto, G.;
Bonifacio, M.;
Rege-Cambrin, G.;
Tiribelli, M.;
Lunghi, F.;
Gozzini, A.;
Pregno, P.;
Abruzzese, E.;
Capodanno, I.;
Bucelli, C.;
Pizzuti, M.;
Artuso, S.;
Iezza, M.;
Scalzulli, E.;
La Barba, G.

Publication type:

Article

NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.

Published in:

Frontiers in Immunology, 2019, p. N.PAG, doi. 10.3389/fimmu.2018.03152

By:

Chang, Ming-Chin;
Cheng, Hung-I;
Hsu, Kate;
Hsu, Yen-Ning;
Kao, Chen-Wei;
Chang, Yi-Fang;
Lim, Ken-Hong;
Chen, Caleb Gonshen

Publication type:

Article

Examination of ototoxicity induced by imatinib, being a tyrosine kinase inhibitor: An experimental study.

Published in:

Indian Journal of Otology, 2020, v. 26, n. 3, p. 141, doi. 10.4103/indianjotol.INDIANJOTOL_129_20

By:

Altuntas, Emine;
Durmus, Kasim;
Bora, Adem;
Turgut, Nergiz;
Terzi, Hatice;
Kutluhan, Ahmet

Publication type:

Article

Nilotinib Induced Recurrent Gastric Polyps: Case Report and Review of Literature.

Published in:

American Journal of Case Reports, 2017, v. 18, p. 794, doi. 10.12659/AJCR.903485

By:

Kassem, Nancy;
Ismail, Omar M.;
Elomri, Halima;
Yassin, Mohamad A.

Publication type:

Article

Bone Marrow CD34+/lin− Cells of Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) After 12 Months of Nilotinib Treatment Exhibit a Different Gene Expression Signature Compared to the Diagnosis and the Corresponding Cells from Healthy Subjects

Published in:

Cancers, 2025, v. 17, n. 6, p. 1022, doi. 10.3390/cancers17061022

By:

Trojani, Alessandra;
Pungolino, Ester;
Di Camillo, Barbara;
Bossi, Luca Emanuele;
Palumbo, Cassandra;
D'adda, Mariella;
Perego, Alessandra;
Turrini, Mauro;
Elena, Chiara;
Borin, Lorenza Maria;
Iurlo, Alessandra;
Malato, Simona;
Spina, Francesco;
Latargia, Maria Luisa;
Spedini, Pierangelo;
Artale, Salvatore;
Anghilieri, Michela;
Carraro, Maria Cristina;
Bucelli, Cristina;
Beghini, Alessandro

Publication type:

Article

Caught in the Crossfire: Unmasking the Silent Renal Threats of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia †.

Published in:

Cancers, 2025, v. 17, n. 1, p. 92, doi. 10.3390/cancers17010092

By:

Benkhadra, Maria;
Ghasoub, Rola;
Hajeomar, Reem;
Alshurafa, Awni;
Qasem, Nabeel Mohammad;
Saglio, Giuseppe;
Cortes, Jorge;
Elkonaissi, Islam;
Kaddoura, Rasha;
Yassin, Mohamed A.

Publication type:

Article

Hematological Adverse Events with Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia: A Systematic Review with Meta-Analysis.

Published in:

Cancers, 2023, v. 15, n. 17, p. 4354, doi. 10.3390/cancers15174354

By:

Kronick, Olivia;
Chen, Xinyu;
Mehra, Nidhi;
Varmeziar, Armon;
Fisher, Rachel;
Kartchner, David;
Kota, Vamsi;
Mitchell, Cassie S.

Publication type:

Article

Renal Safety Profile of BCR-ABL Tyrosine Kinase Inhibitors in a Real-Life Setting: A Study Based on Vigibase ® , the WHO Pharmacovigilance Database.

Published in:

Cancers, 2023, v. 15, n. 7, p. 2041, doi. 10.3390/cancers15072041

By:

Cellier, Morgane;
Bourneau-Martin, Delphine;
Abbara, Chadi;
Crosnier, Alexandre;
Lagarce, Laurence;
Garnier, Anne-Sophie;
Briet, Marie

Publication type:

Article

Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.

Published in:

Cancers, 2021, v. 13, n. 7, p. 1643, doi. 10.3390/cancers13071643

By:

Mohanavelu, Prahathishree;
Mutnick, Mira;
Mehra, Nidhi;
White, Brandon;
Kudrimoti, Sparsh;
Hernandez Kluesner, Kaci;
Chen, Xinyu;
Nguyen, Tim;
Horlander, Elaina;
Thenot, Helena;
Kota, Vamsi;
Mitchell, Cassie S.;
Guilhot, François;
Di Maio, Massimo

Publication type:

Article

FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma.

Published in:

Cancers, 2020, v. 12, n. 5, p. 1062, doi. 10.3390/cancers12051062

By:

Tétu, Pauline;
Delyon, Julie;
André, Jocelyne;
Reger de Moura, Coralie;
Sabbah, Malak;
Ghanem, Ghanem E;
Battistella, Maxime;
Mourah, Samia;
Lebbé, Céleste;
Dumaz, Nicolas

Publication type:

Article

Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: An Analysis of the FDA Adverse Event Reporting System Database (FAERS).

Published in:

Cancers, 2020, v. 12, n. 4, p. 826, doi. 10.3390/cancers12040826

By:

Cirmi, Santa;
El Abd, Asmae;
Letinier, Louis;
Navarra, Michele;
Salvo, Francesco

Publication type:

Article

Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis.

Published in:

Leukemia Research & Treatment, 2015, p. 1, doi. 10.1155/2015/982395

By:

Rochau, Ursula;
Kluibenschaedl, Martina;
Stenehjem, David;
Kuan-Ling, Kuo;
Radich, Jerald;
Oderda, Gary;
Brixner, Diana;
Siebert, Uwe

Publication type:

Article

Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.

Published in:

PLoS Neglected Tropical Diseases, 2020, v. 14, n. 7, p. 1, doi. 10.1371/journal.pntd.0008361

By:

Kodama, Daisuke;
Tanaka, Masakazu;
Matsuzaki, Toshio;
Izumo, Kimiko;
Nakano, Nobuaki;
Matsuura, Eiji;
Saito, Mineki;
Nagai, Masahiro;
Horiuchi, Masahisa;
Utsunomiya, Atae;
Takashima, Hiroshi;
Kubota, Ryuji;
Izumo, Shuji

Publication type:

Article

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.

Published in:

2023

By:

Jiang, Qian;
Li, Zongru;
Qin, Yazhen;
Li, Weiming;
Xu, Na;
Liu, Bingcheng;
Zhang, Yanli;
Meng, Li;
Zhu, Huanling;
Du, Xin;
Chen, Suning;
Liang, Yang;
Hu, Yu;
Liu, Xiaoli;
Song, Yongping;
Men, Lichuang;
Chen, Zi;
Niu, Qian;
Wang, Hengbang;
Lu, Ming

Publication type:

Correction Notice

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.

Published in:

2022

By:

Jiang, Qian;
Li, Zongru;
Qin, Yazhen;
Li, Weiming;
Xu, Na;
Liu, Bingcheng;
Zhang, Yanli;
Meng, Li;
Zhu, Huanling;
Du, Xin;
Chen, Suning;
Liang, Yang;
Hu, Yu;
Liu, Xiaoli;
Song, Yongping;
Men, Lichuang;
Chen, Zi;
Niu, Qian;
Wang, Hengbang;
Lu, Ming

Publication type:

Correction Notice

Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial.

Published in:

Journal of Hematology & Oncology, 2022, v. 15, n. 1, p. 1, doi. 10.1186/s13045-022-01334-z

By:

Jiang, Qian;
Li, Zongru;
Qin, Yazhen;
Li, Weiming;
Xu, Na;
Liu, Bingcheng;
Zhang, Yanli;
Meng, Li;
Zhu, Huanling;
Du, Xin;
Chen, Suning;
Liang, Yang;
Hu, Yu;
Liu, Xiaoli;
Song, Yongping;
Men, Lichuang;
Chen, Zi;
Niu, Qian;
Wang, Hengbang;
Lu, Ming

Publication type:

Article

Incidence of cardiovascular events in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors.

Published in:

Acta Cardiologica, 2022, v. 77, n. 2, p. 130, doi. 10.1080/00015385.2021.1888017

By:

Casavecchia, Grazia;
Spinosa, Giuseppina;
De Gennaro, Luisa;
Zicchino, Stefano;
Gravina, Matteo;
Magnesa, Michele;
Di Biase, Matteo;
Brunetti, Natale Daniele

Publication type:

Article

Imatinib Attenuates Pentylenetetrazole Kindled and Pilocarpine Induced Recurrent Spontaneous Seizures in Mice.

Published in:

Neurochemical Research, 2023, v. 48, n. 2, p. 418, doi. 10.1007/s11064-022-03758-y

By:

Singh, Shareen;
Singh, Thakur Gurjeet

Publication type:

Article

Cardiovascular Safety of Nilotinib in Alzheimer Disease.

Published in:

2021

By:

Tan, Sean;
Baggio, Diva;
Shortt, Jake;
Ko, Brian

Publication type:

Letter

Reply to "Cardiovascular Safety of Nilotinib in Alzheimer's Disease".

Published in:

Annals of Neurology, 2021, v. 89, n. 1, p. 196, doi. 10.1002/ana.25946

By:

Moussa, Charbel

Publication type:

Article

Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease.

Published in:

2020

By:

Turner, Raymond S.;
Hebron, Michaeline L.;
Lawler, Abigail;
Mundel, Elizabeth E.;
Yusuf, Nadia;
Starr, J. Nathan;
Anjum, Muhammad;
Pagan, Fernando;
Torres‐Yaghi, Yasar;
Shi, Wangke;
Mulki, Sanjana;
Ferrante, Dalila;
Matar, Sara;
Liu, Xiaoguang;
Esposito, Giuseppe;
Berkowitz, Frank;
Jiang, Xiong;
Ahn, Jaeil;
Moussa, Charbel;
Torres-Yaghi, Yasar

Publication type:

journal article

Inhibition of discoidin domain receptor (DDR)-1 with nilotinib alters CSF miRNAs and is associated with reduced inflammation and vascular fibrosis in Alzheimer's disease.

Published in:

Journal of Neuroinflammation, 2023, v. 20, n. 1, p. 1, doi. 10.1186/s12974-023-02802-0

By:

Stevenson, Max;
Varghese, Rency;
Hebron, Michaeline L.;
Liu, Xiaoguang;
Ratliff, Nick;
Smith, Amelia;
Turner, R. Scott;
Moussa, Charbel

Publication type:

Article

Eruption of squamous cell carcinomas after beginning nilotinib therapy.

Published in:

Dermatology Online Journal, 2020, v. 26, n. 6, p. 1, doi. 10.5070/d3266049318

By:

Crain, Caroline B.;
Winsett, Frank T.;
Woolridge, Katelyn F.;
Wilson, Janice M.;
Goodwin, Brandon P.

Publication type:

Article

An unusual presentation of localized bullous morphea.

Published in:

Dermatology Online Journal, 2020, v. 26, n. 6, p. 1, doi. 10.5070/d3266049323

By:

Lahouel, Maha;
Soua, Yosra;
Njim, Leila;
Belhadjali, Hichem;
Youssef, Monia;
Zili, Jamelleddine

Publication type:

Article

The tyrosine kinase inhibitor nilotinib is more efficient than mitotane in decreasing cell viability in spheroids prepared from adrenocortical carcinoma cells.

Published in:

Cancer Cell International, 2018, v. 18, p. 1, doi. 10.1186/s12935-018-0527-x

By:

Silveira, Elaine;
Cavalcante, Isadora Pontes;
Kremer, Jean Lucas;
de Mendonça, Pedro Omori Ribeiro;
Lotfi, Claudimara Ferini Pacicco

Publication type:

Article

The effect of nilotinib plus arsenic trioxide on the proliferation and differentiation of primary leukemic cells from patients with chronic myoloid leukemia in blast crisis.

Published in:

Cancer Cell International, 2015, v. 15, n. 1, p. 1, doi. 10.1186/s12935-015-0158-4

By:

Wei Wang;
Fei-fei Lv;
Yan Du;
Nannan Li;
YaLing Chen;
LiHong Chen

Publication type:

Article

Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA).

Published in:

2021

By:

Hallal, Mahmoud;
Braga-Lagache, Sophie;
Jankovic, Jovana;
Simillion, Cedric;
Bruggmann, Rémy;
Uldry, Anne-Christine;
Allam, Ramanjaneyulu;
Heller, Manfred;
Bonadies, Nicolas

Publication type:

journal article

Life cycle assessment of pharmaceutical and clinical packaging required for medication administration practices.

Published in:

International Journal of Life Cycle Assessment, 2024, v. 29, n. 3, p. 416, doi. 10.1007/s11367-023-02270-x

By:

Baehr, Julian;
Göllner-Völker, Laura;
Baehr, Michael;
Muthukumar, Hariharan;
Lapa, Nuno;
Schebek, Liselotte

Publication type:

Article

Combination therapeutics of Nilotinib and radiation in acute lymphoblastic leukemia as an effective method against drug-resistance.

Published in:

PLoS Computational Biology, 2017, v. 13, n. 7, p. 1, doi. 10.1371/journal.pcbi.1005482

By:

Kaveh, Kamran;
Takahashi, Yutaka;
Farrar, Michael A.;
Storme, Guy;
Guido, Marcucci;
Piepenburg, Jamie;
Penning, Jackson;
Foo, Jasmine;
Leder, Kevin Z.;
Hui, Susanta K.

Publication type:

Article

Analytical control of imatinib in bioanalytical samples using graphene quantum dots sensing.

Published in:

Analytical & Bioanalytical Chemistry, 2024, v. 416, n. 30, p. 7267, doi. 10.1007/s00216-024-05346-1

By:

García-Trejo, María A.;
Castañeda, Gregorio;
Ríos, Ángel

Publication type:

Article

A preclinical study demonstrating the efficacy of nilotinib in inhibiting the growth of pediatric high-grade glioma.

Published in:

Journal of Neuro-Oncology, 2015, v. 122, n. 3, p. 471, doi. 10.1007/s11060-015-1744-y

By:

Au, Karolyn;
Singh, Sanjay;
Burrell, Kelly;
Sabha, Nesrin;
Hawkins, Cynthia;
Huang, Annie;
Zadeh, Gelareh

Publication type:

Article

Efficacy and selectivity of nilotinib on NF1-associated tumors in vitro.

Published in:

Journal of Neuro-Oncology, 2014, v. 116, n. 2, p. 231, doi. 10.1007/s11060-013-1295-z

By:

Jiang, Wei;
Schnabel, Claudia;
Spyra, Melanie;
Mautner, Victor-F;
Friedrich, Reinhard;
Hagel, Christian;
Manley, Paul;
Kluwe, Lan

Publication type:

Article